BMYMP - Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions
- Cosibelimab BLA submission to FDA for cutaneous squamous cell carcinoma is expected in late 2022, with MAA to the European Medicines Agency shortly thereafter.
- Cosibelimab regulatory applications are possible because of obtaining a confirmed objective response rate of 47.4% in patients with cutaneous squamous cell carcinoma.
- Cosibelimab holds the potential to disrupt the $30 billion PD-(L)1 class of drugs.
- Cosibelimab is also being developed to treat patients with non-small cell lung cancer, with a global market that is expected to grow to $11.87 billion by 2028.
For further details see:
Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions